Comparison of letrozole with gonadotropin-releasing hormone agonist in frozen embryo transfer after recurrent implantation failure: An RCT.

Autor: Khadem Ghaebi N; Department of Obstetrics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran., Mahmoudiniya M; Department of Obstetrics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran., Najaf Najafi M; Imam Reza Clinical Research Units, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran., Zohdi E; Department of Obstetrics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran., Attaran M; Department of Obstetrics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Jazyk: angličtina
Zdroj: International journal of reproductive biomedicine [Int J Reprod Biomed] 2020 Feb 27; Vol. 18 (2), pp. 105-112. Date of Electronic Publication: 2020 Feb 27 (Print Publication: 2020).
DOI: 10.18502/ijrm.v18i2.6417
Abstrakt: Background: The use of frozen embryo transfer (FET) is increasing worldwide in the treatment of infertility by in vitro fertilization. Different methods of endometrial preparation for FET have been suggested.
Objective: The aim of this study was to compare the pregnancy outcomes after treatment with letrozole and those after treatment with the combination of gonadotropin-releasing hormone (GnRH) agonist and estradiol in FET.
Materials and Methods: This randomized controlled trial study was conducted on 142 infertile women with a history of previous FET failure. Participants were randomly assigned to two groups (n = 71 each). The GnRH group received 500 µg of buserelin plus 4mg estradiol (which increased to 8 mg if endometrial thickness was less than 5 mm), and the letrozole group received 5 mg of letrozole plus 75 IU of recombinant human follicle-stimulating hormone). At least two high-quality embryos were transferred to each subject in both groups. The outcome measures were clinical pregnancy rate and fetal heart rate detection.
Results: Subjects in the study groups had similar demographic characteristics and baseline clinical condition. Mean endometrial thickness in the letrozole and GnRH agonist groups were 8.90 ± 0.88 mm and 8.99 ± 0.85 mm, respectively (p = 0.57). The number of positive results of the beta human chorionic gonadotropin test and detection of fetal heartbeat were not significantly different between the groups (p > 0.05).
Conclusion: The administration of letrozole and GnRH may produce similar pregnancy outcomes in FET.
Competing Interests: None
(Copyright © 2020 Khadem Ghaebi et al.)
Databáze: MEDLINE
Externí odkaz: